Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: A pathway to metastatic progression in human breast cancer

International Journal of Cancer

Volumn 86, Issue 3, 2000, Pages 142-147

  Sierra, Angels ^a   Castellsagué, Xavier ^a   Escobedo, Agustín ^a   Lloveras, Belen ^a   García Ramirez, Marta ^b   Moreno, Abelardo ^a   Fabra, Angels ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN P53; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; MYC PROTEIN; PROGESTERONE RECEPTOR;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL SURVIVAL; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MUTATION; ONCOGENE; ONCOGENE C ERB; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; NICK END LABELING; PAGET NIPPLE DISEASE; PATHOLOGY; PROTO ONCOGENE; STATISTICAL MODEL;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; IN SITU NICK-END LABELING; LINEAR MODELS; LYMPHATIC METASTASIS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0034688878     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(20000320)89:2<142::aid-ijc7>3.0.co;2-b     Document Type: Article

References (23)

1. ALARCON, R.M., RUPNOW, B.A., GRAEBER, T.G., KNOX, S.J. and GIACCIA, A.J., Modulation of c-Myc activity and apoptosis in vivo. Cancer Res., 56, 4315-4319 (1996).
2. AMUNDADOTTIR, L.T., NASS, S.J., BERCHEM, G.J., JOHNSON, M.D. and DICKSON, R.B., Cooperation of TGFα and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Oncogene, 13, 757-765 (1996).
3. BISSONNETTE, R.P., ECHEVERRI, F., MAHBOUBI, A. and GREEN, D.R., Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature (Lond.), 359, 552-554 (1992).
4. BRESLOW, N.E. and DAY, N.E., Statistical methods in cancer research. Vol. I, The analysis of case-control studies, IARC Sci. Publ. 32, IARC, Lyon (1980).
5. L, promotes susceptibility to mutagenesis. Oncogene, 13, 1489-1497 (1996).
6. DEL BUFALO, D., BIROCCIO, A., LEONETTI, C. and ZUPI, G., Bcl-2 over-expression enhances the metastatic potential of a human breast cancer line. FASEB J., 11, 947-953 (1997).
7. HALDAR, S., NEGRIN, M., MONNE, M., SABBIONI, S. and CROCE, C.M., Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res., 54, 2095-2097 (1994).
8. LEEK, R.D., KAKLAMANIS, L., PEZZELLA, F., GATTER, K.C. and HARRIS, A.L., bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Brit. J. Cancer, 69, 135-139 (1994).
9. LIU, Y., NAUMOVSKI, L. and HANAWALT, P., Nucleotide excision repair capacity is attenuated in human promyelocytic HL60 cells that over-express BCL2. Cancer Res., 57, 1650-1653 (1997).
10. LU, Q., ABEL, P., FOSTER, C.S. and LALANI, E., bcl-2: role in epithelial differentiation and ONCOGENESIS. Hum. Pathol., 27, 102-110 (1996).
11. MARIN, M.C., HSU, B., STEPHENS, C., BRISBAY, S. and MCDONNELL, T.J., The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo. Exp. Cell Res., 217, 240-247 (1995).
12. MINN, A.J., SWAIN, R.E., MA, A. and THOMPSON, C.B., Recent progress on the regulation of apoptosis by Bcl-2 family members. Adv. Immunol., 70, 245-279 (1998).
13. MORENO, A., LLOVERAS, B., FIGUERAS, A., ESCOBEDO, A., RAMÓN, J.M., SIERRA, A. and FABRA, A., Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. Mod. Pathol., 10, 1088-1092 (1997).
14. NASS, S.J. and DICKSON, R.B., Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res. Treat., 44, 1-22 (1997).
15. SHTIVELMAN, E., A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Oncogene, 14, 2167-2173 (1997).
16. SIERRA, A., CASTELLSAGÚ, X., ESCOBEDO, A., LLOVERAS, B., MORENO, A. and FABRA, A., Expression of death-related genes and their relationship with loss of apoptosis in T1 ductal breast carcinomas. Int. J. Cancer, 79, 103-110 (1998).
17. SIERRA, A., CASTELLSAGÚ, X., ESCOBEDO, A., MORENO, A., DRUDIS, T. and FABRA, A., Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas. Breast Cancer Res. Treat., 54, 39-45 (1999).
18. SIERRA, A., CASTELLSAGÚ, X., TÓRTOLA, S., ESCOBEDO, A., LLOVERAS, B., PEINADO, M.A., MORENO, A. and FABRA, A., Apoptosis loss and Bcl-2 expression: key determinants of lymph node metastases in T1 breast cancer. Clin. Cancer Res., 2, 1887-1894 (1996).
19. SIERRA, A., LLOVERAS, B., CASTELLSAGÚ, X., MORENO, L., GARCÍA-RAMIREZ, M. and FABRA, A., Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int. J. Cancer, 60, 54-60 (1995).
20. SILVESTRINI, R., VENERONI, S., DAIDONE, M.G., BENINI, E., BORACCHI, P., MEZZETTI, M., DI FRONZO, G., RILKE, F. and VERONESI, U., The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymphnode-negative breast cancer patients. J. nat. Cancer Inst., 86, 499-504 (1994).
21. STRASSER, A., The role of physiological cell death in neoplastic transformation and in anti-cancer therapy. Int. J. Cancer, 81, 505-511 (1999).
22. VAN DE VIJVER, M.J., Molecular genetic changes in human breast cancer. Adv. Cancer Res., 61, 25-56 (1993).
23. YIN, D.X. and SCHIMKE, R.T., Inhibition of apoptosis by over-expressing Bcl-2 enhances gene amplification by a mechanism independent of aphidicolin pretreatment. Proc. nat. Acad. Sci. (Wash.), 93, 3394-3398 (1996).